Chemical volatilization device

The chemical volatilization device with a protruding and symmetrical container design stabilizes chemical volatilization, addressing direction-dependent variations and improving pest control effectiveness.

JP7582870B2Active Publication Date: 2024-11-13EARTH CORP
View PDF 9 Cites 0 Cited by

Patent Information

Application Number
JP2020572344
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2019-02-14
Filing Date
2020-02-14
Publication Date
2024-11-13
Estimated Expiration
2040-02-14

AI Technical Summary

Technical Problem

Conventional chemical volatilization devices suffer from variations in chemical volatilization amounts and ranges due to air flow direction, affecting pest control effectiveness.

Method used

A chemical volatilization device with a container having a protruding shape in its cross-section, featuring a curved design and symmetrical protrusions on both sides, which houses a drug volatilization body, ensuring consistent volatilization regardless of air flow direction.

Benefits of technology

The device stabilizes chemical volatilization amounts and ranges, enhancing pest control efficacy by minimizing variations caused by air flow direction.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007582870000002
    Figure 0007582870000002
  • Figure 0007582870000003
    Figure 0007582870000003
  • Figure 0007582870000004
    Figure 0007582870000004
Patent Text Reader

Abstract

The drug volatilization device (10) includes a drug volatilization body (20) holding a drug that is volatile at room temperature, and a container (30) having openings (31c, 32c). The container (30) has a plate-like structure configured such that, in a predetermined cross section along its thickness direction, portions (31b, 32b, 31d) away from peripheral portions (31a, 32a) have a protruding shape that protrudes in the thickness direction beyond the peripheral portions (31a, 32a). The drug volatilization body (20) has a curved shape that conforms to the protruding shape.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to a drug volatilization device comprising a drug volatilization body that holds a drug that is volatile at room temperature, and a container that contains the drug volatilization body inside and has an opening that exposes the drug volatilization body to the outside. [Background technology]

[0002] Conventionally, for the purpose of pest control, etc., a drug volatilization device in which a drug volatilizer holding a drug is accommodated in a container has been used. In general, this type of drug volatilization device is designed to volatilize the drug naturally evaporated from the drug volatilizer into the air (wind) flowing around the drug volatilization device by providing an opening in the container that exposes the drug volatilizer to the outside (see, for example, Patent Documents 1 to 3). [Prior art documents] [Patent documents]

[0003] [Patent Document 1] Japanese Patent Publication No. 2009-022164 [Patent Document 2] Japanese Patent Publication No. 2014-135910 [Patent Document 3] Japanese Patent Application Publication No. 2017-018034 Summary of the Invention [Problem to be solved by the invention]

[0004] In the above-mentioned conventional drug volatilization device, the drug is volatilized by using the air (wind) flowing around the drug volatilization device, and the amount and range of the drug volatilization may vary depending on the direction of the air flow (wind direction). In particular, according to the study conducted by the inventor, when the container of the drug volatilization device has a simple flat plate-like structure, when air flows into the drug volatilization device from the side, the amount and range of the drug volatilization are inferior to when air flows into the drug volatilization device from the front side. When the amount and range of the drug volatilization are inferior, the effect of pest control, etc. is naturally impaired. From the viewpoint of properly exerting the effect of the drug volatilization device, it is desired to suppress the variation in the amount of drug volatilization caused by the direction of the air flowing around the drug volatilization device (wind direction).

[0005] One object of the present invention is to provide a drug volatilization device that can suppress variations in the amount of drug volatilization, etc., caused by the direction (wind direction) of air flowing around the drug volatilization device. [Means for solving the problem]

[0006] [1] In a first aspect of the present invention, a drug volatilization device is The present invention comprises a drug volatilizer that holds a drug that is volatile at room temperature, and a container that contains the drug volatilizer inside and has an opening that exposes the drug volatilizer to the outside, The container comprises: The container has a plate-like structure configured such that, in a predetermined cross section along the thickness direction of the container, a portion away from a peripheral portion of the container has a protruding shape that protrudes in the thickness direction beyond the peripheral portion, The drug volatilizer is It has a curved shape that fits the protruding shape.

[0007] [2] In a second aspect of the present invention, in the drug volatilization device according to the first aspect, The container comprises: Both the surface on one side and the surface on the other side in the thickness direction are configured to have the protruding shape.

[0008] [3] In a third aspect of the present invention, in the drug volatilization device according to the first or second aspect, The container comprises: The protruding shape in the cross section is configured to be symmetrical with respect to the central portion of the container.

[0009] [4] In a fourth aspect of the present invention, in a drug volatilization device according to any one of the first to third aspects, The drug is It contains at least one selected from the group of drugs consisting of profluthrin, empenthrin, transfluthrin and metofluthrin.

[0010] As a result of the inventor's investigation of the above-mentioned first aspect, it was found that when a chemical volatilizer is contained in a plate-shaped container having an opening, a container having a specific protruding cross-sectional shape (i.e., a shape in which the part away from the periphery of the container protrudes in the thickness direction from the periphery) is used, and it is found that excellent effects such as pest control can be achieved regardless of the direction of air (wind direction) flowing around the chemical volatilizer. Specifically, it was found that the amount and range of chemical volatilization do not differ excessively (i.e., the variation in effect can be suppressed) even when air flows into the chemical volatilizer from the side or the front side. Therefore, the chemical volatilizer of this configuration can suppress the variation in the amount of chemical volatilization, etc. caused by the direction of air (wind direction) flowing around the chemical volatilizer.

[0011] As a result of the inventor's investigation of the second aspect, it became clear that, as an example of a container having a cross-sectional shape according to the first aspect, both the surface on one side and the surface on the other side in the thickness direction of the container are configured to have the above-mentioned protruding shape, thereby suppressing the variation in the amount of volatilization of the medicine. Therefore, with this configuration, the effect of the medicine volatilization device is properly exhibited.

[0012] As a result of the inventor's investigation of the third aspect, it became clear that by configuring the cross-sectional shape of the container to be a line-symmetric shape with respect to the center part of the container, the variation in the amount of volatilization of the medicine can be further suppressed compared to when the cross-sectional shape of the container is not a line-symmetric shape. Therefore, with this configuration, the effect of the medicine volatilization device can be more appropriately exhibited.

[0013] According to the fourth aspect, by using a pyrethroid-based pesticide (i.e., at least one selected from profluthrin, empenthrin, transfluthrin and metofluthrin) that has an excellent control effect against insects, etc., pest control can be appropriately carried out using the pesticide volatilization device of this configuration. Effect of the Invention

[0014] According to the present invention, a drug volatilization device can be provided that can suppress variations in the amount of drug volatilization, etc., caused by the direction (wind direction) of air flowing around the drug volatilization device.

[0015] The present invention has been briefly described above. The details of the present invention will be further clarified by reading the following description of the preferred embodiment of the present invention (hereinafter referred to as "embodiment") with reference to the accompanying drawings. [Brief description of the drawings]

[0016] [Figure 1] FIG. 1 is an external view of a drug volatilization device according to an embodiment of the present invention. [Diagram 2] FIG. 2 is an exploded perspective view of the drug volatilization device of FIG. [Diagram 3] 3(a) and 3(b) are cross-sectional views taken along the line AA in FIG. [Figure 4] Figure 4(a) is a conceptual diagram showing the air flow around the drug volatilization device of Figure 1 when air flows into the device from the side, and Figure 4(b) is a conceptual diagram showing the air flow around the drug volatilization device of Figure 1 when air flows into the device from the front. [Diagram 5]FIG. 5 is a schematic diagram showing an evaluation test conducted using the drug volatilization device of FIG. [Figure 6] Figure 6(a) is a diagram corresponding to Figures 3(a) and 3(b) for a drug volatilization device related to a first variant of the present invention, and Figure 6(b) is a diagram corresponding to Figures 3(a) and 3(b) for a drug volatilization device related to a second variant of the present invention. [Figure 7] Figure 7(a) is a diagram corresponding to Figures 3(a) and 3(b) for a drug volatilization device related to a third variant of the present invention, and Figure 7(b) is a diagram corresponding to Figures 3(a) and 3(b) for a drug volatilization device related to a fourth variant of the present invention. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0017] <Embodiment> Hereinafter, the drug volatilization device 10 according to the embodiment of the present invention will be described with reference to the drawings. For convenience of explanation, as shown in FIG. 1, the longitudinal direction of the drug volatilization device 10 is the "vertical direction", one direction perpendicular to the "vertical direction" is the "width direction", and one direction perpendicular to the "vertical direction" and the "width direction" is the "thickness direction". In addition, one side of the "thickness direction" where the drug volatilization device 10 protrudes in a convex shape is the "front side", and the other side is the "back side".

[0018] The drug volatilization device 10 according to this embodiment has a vertically long rectangular shape in the vertical direction in Fig. 1. However, this shape is merely an example, and the shape of the drug volatilization device 10 is not limited to the shape shown in Fig. 1. For example, the drug volatilization device 10 may have a horizontally long rectangular shape in the width direction in Fig. 1, a square shape, or another polygonal shape, or may have a circular or elliptical shape.

[0019] (Structure of drug volatilization device) As shown in Figures 1, 2, 3(a) and 3(b), the drug volatilization device 10 has a drug volatilization body 20 that holds a drug that is volatile at room temperature, and a plate-shaped container 30 that defines an internal storage space S for storing the drug volatilization body 20. The drug volatilization device 10 has a rectangular shape in which the height (length in the vertical direction in Figure 1) is longer than the width (length in the width direction) as a whole, and has a curved shape such that the central portion in the width direction protrudes toward the front side.

[0020] More specifically, the container 30 has a front housing 31, a rear housing 32, and a string-like hanging part 33 attached to the rear housing 32. As shown in Fig. 3(a) and Fig. 3(b) in particular, the front housing 31 has a protruding shape in a cross section along the thickness direction of the container 30, in which a central part 31b away from peripheral parts 31a on both sides in the width direction of the container 30 protrudes toward the front side in the thickness direction more than the peripheral parts 31a. In this example, in a predetermined range from the peripheral parts 31a toward the inside in the width direction, the front housing 31 has a substantially flat flat region R1, and in a range from the central part 31b toward the flat region R1, the front housing 31 has a curved region R2 that is gently curved so as to be recessed inward in the width direction.

[0021] Here, in a cross section taken along the thickness direction of container 30 as shown in FIG. 3(a), if the maximum length A of container 30 in the thickness direction is divided by the maximum length Z of container 30 in the width direction (A / Z) and this is defined as the "protrusion amount X," then protrusion amount X (=A / Z) is preferably 0.1 to 10, and more preferably 0.2 to 5.

[0022] Furthermore, as shown in FIG. 3(b), in a cross section along the thickness direction of the container 30, with respect to a center position P of the protruding end of the central portion 31b of the front housing 31 and end positions Q and R in the width direction on the rear surface of the peripheral portion 32a of the rear housing 32, if the angle θ formed by a line segment connecting one of the end positions Q and R (Q in this example) to the center position P and a line segment connecting both the end positions Q and R is defined as the "protrusion angle θ," then the protrusion angle θ is preferably 11 to 87 degrees, and more preferably 21 to 84 degrees.

[0023] Similar to the front housing 31, the rear housing 32 has a protruding shape in which a central portion 32b away from peripheral portions 32a on both sides in the width direction of the container 30 protrudes toward the front side in the thickness direction more than the peripheral portions 32a in the cross section along the thickness direction of the container 30. In this example, the rear housing 32 has a flat region R1 and a curved region R2 similar to those of the front housing 31.

[0024] Between the front housing 31 and the rear housing 32, a storage space S having a shape corresponding to the above-mentioned protruding shape is defined. The drug volatilizer 20 is stored in the storage space S, so that the drug volatilizer 20 has a curved shape that follows the protruding shapes of the front housing 31 and the rear housing 32. Specifically, in this example, as shown in FIG. 2, the drug volatilizer 20 is sandwiched between the front housing 31 and the rear housing 32, and the front housing 31 and the rear housing 32 are joined in a state where they are overlapped in the thickness direction, so that the drug volatilizer 20 is stored in the storage space S. In this example, the drug volatilizer 20 has a degree of flexibility that allows it to be stored in the storage space S as described above (details will be described later).

[0025] The front housing 31 and the rear housing 32 may be joined by, for example, a method using a locking member, a method using heat fusion, a method using an adhesive, etc. As a method using a locking member, for example, a method in which a claw portion (not shown) is provided on one of the front housing 31 and the rear housing 32 and a recess is provided on the other, and the claw portion is locked in the recess. The front housing 31 and the rear housing 32 may be configured to be detachable by using such a locking member, or may be configured to be non-detachable by heat fusion or adhesion.

[0026] As shown in FIG. 1 and FIG. 2, the front side housing 31 has a plurality of openings 31c that expose the drug volatilizer 20 contained in the storage space S to the outside. Specifically, in this example, four openings 31c are arranged vertically on one side of the width direction of the central part 31b of the front side housing 31, and four openings 31c are arranged vertically on the other side of the width direction of the central part 31b. Each opening 31c extends in the width direction while curving along the shape of the curved region R2 (see FIG. 3(a) and FIG. 3(b)) of the front side housing 31. The front side housing 31 may have an opening 31c in the central part 31b.

[0027] As with the front housing 31, in this example, four openings 32c are arranged vertically on one widthwise side of the central portion 32b of the rear housing 32, and four openings 32c are arranged vertically on the other widthwise side of the central portion 32b. Each opening 32c extends in the widthwise direction while curving along the shape of the curved region R2 (see FIGS. 3(a) and 3(b)) of the rear housing 32. The rear housing 32 may have an opening 32c in the central portion 32b.

[0028] However, the number, arrangement and shape of the openings 31c and 32c are not particularly limited as long as the air around the drug volatilization device 10 can contact the drug volatilizer 20 through the openings 31c and 32c. For example, the number, arrangement and shape of the openings 31c and 32c can be appropriately adjusted from the viewpoint of adjusting the amount of drug volatilization and the range of volatilization. In addition, in this example, the front side housing 31 and the rear side housing 32 are provided with openings 31c and 32c having approximately the same number, arrangement and shape, but the front side housing 31 and the rear side housing 32 may be provided with openings 31c and 32c having different numbers, arrangements and shapes. Furthermore, the material constituting the front side housing 31 and the rear side housing 32 is not particularly limited, and for example, resin, metal, glass, paper, wood, ceramics, etc. may be used.

[0029] The hanging part 33 is used to hang the drug volatilization device 10 at a predetermined location indoors or outdoors. For example, by hanging the drug volatilization device 10 using the hanging part 33 around an opening such as an entrance or window of a building where flying pests such as mosquitoes and flies can enter, it is possible to control these pests. In addition, the drug volatilization device 10 may be used for purposes such as fragrance, deodorization, and sterilization in a toilet or room.

[0030] As an example of the drug volatilizer 20 that holds the drug, a net made of a fiber material can be mentioned. This net generally has many air holes and has an excellent drug volatilization effect. The fiber material used for the net can be manufactured, for example, by knitting short or long fiber threads using a technique such as lace knitting or stockinette knitting. Examples of the material for the thread include natural fibers such as pulp, cotton, wool, hemp, and silk, polypropylene, polyethylene, polyamide, polyethylene terephthalate, polybutylene terephthalate, polysulfone, rayon, methacrylic acid resin, and biodegradable resin (for example, polyglycolic acid, polylactic acid, and poly(β-hydroxybutyric acid)). One or more of these materials may be mixed and used. In particular, from the viewpoint of strength, processability, and the like, it is preferable to use polyethylene terephthalate, polypropylene, polybutylene terephthalate, and polyethylene. Furthermore, for example, additives such as antifungal agents, pigments, ultraviolet absorbers, and fragrances may be included in the fiber material.

[0031] Regarding the degree of opening of the net using the fiber material, the ratio of the total area of ​​the ventilation hole portion to the total area of ​​the net is preferably 5 to 80%, more preferably 10 to 50%. Note that, the smaller the degree of opening, the lower the volatility of the drug tends to be, and the larger the degree of opening, the lower the amount of drug retained per unit area tends to be.

[0032] The chemical held by the chemical volatilizer 20 is a chemical that can volatilize at room temperature, and may be appropriately selected according to the purpose from various chemicals such as various pest control agents (insecticides and repellents, etc.), fragrances, deodorants, disinfectants, antifungal agents, etc., and is not particularly limited. Only one type of chemical may be used, or two or more types may be used.

[0033] Examples of pest control agents include various insecticides, repellents, and insect growth regulators, such as organophosphorus, carbamate, and pyrethroid insecticides. Organophosphorus insecticides include DDVP and diazinon, carbamate insecticides include propoxur, and pyrethroid insecticides include phthalthrin, prallethrin, tefluthrin, transfluthrin, metofluthrin, dimefluthrin, mepafluthrin, profluthrin, empenthrin, and telarethrin. Among these, profluthrin, empenthrin, transfluthrin, and metofluthrin are preferred because of their excellent insecticidal effect. Other pest control agents include plant essential oils, terpenes, and their isomers and derivatives.

[0034] Examples of the fragrances include essential oils such as lavender oil, musk, dragon jasmine, abies oil, citronella oil, eucalyptus oil, fennel oil, garlic oil, ginger oil, grapefruit oil, lemon oil, lemongrass oil, nutmeg oil, peppermint oil, orange oil, turpentine oil, and sage oil; and perfumes such as pinene, limonene, linalool, geraniol, citronellal, borneol, benzyl alcohol, anise alcohol, anethole, eugenol, aldehyde, citral, citronellal, vanillin, carvone, ketone, menthone, acetophenone, coumarin, cineol, ethyl acetate, octyl acetate, linalyl acetate, butylcyclohexyl acetate, butylcycloheptyl acetate, isopropyl isobutyrate, allyl caproate, ethyl benzoate, methyl cinnamate, and methyl salicylate.

[0035] Examples of deodorants and anti-odors include benzyl acetate, benzyl propionate, amylcinnamic aldehyde, anisic aldehyde, diphenyl oxide, methyl benzoate, ethyl benzoate, methyl phenylacetate, ethyl phenylacetate, neolin, safrole, citronella oil, and lemongrass oil.

[0036] Examples of disinfectants include IPMP (isopropylmethylphenol), PCMX (p-chloro-m-xylenol), AIT (allyl isothiocyanate), hinokitiol, and stabilized chlorine dioxide.

[0037] If necessary, various additives may be added to the drug within the scope of not impairing the effects of the present invention. Examples of additives include efficacy enhancers, volatilization rate enhancers, and stabilizers. Only one type of additive may be used, or two or more types may be used.

[0038] Examples of the volatilization rate enhancer include phenethyl isothiocyanate, etc. Examples of the stabilizer include 3,5-di-t-butyl-4-hydroxytoluene, 3-t-butyl-4-hydroxyanisole, mercaptobenzimidazole, dilauryl-thio-di-propionate, 2,2'-methylene-bis-(6-t-butyl-4-methylphenol), 4,4'-methylene-bis-(2,6-di-t-butylphenol), 4,4'-thio-bis-(6-t-butyl-3-methylphenol), phenyl-β-naphthylamine, 2-t-butyl-4-methoxyphenol, stearyl-β-(3,5-di-t-butyl-4-hydroxyphenyl)propionate, α-tocopherol, ascorbic acid, and erythorbic acid.

[0039] The method of retaining the drug in the drug volatilizer 20 is not particularly limited. For example, a method of preparing a solution in which the drug is dissolved in a solvent and immersing the above-mentioned net in the solution to impregnate the drug, a method of spraying or dropping the solution or the drug raw material onto the net to impregnate the net with the drug, and a method of kneading the drug into the net can be used. Furthermore, if necessary, after the drug is impregnated into the net, the solvent may be removed by drying or the like.

[0040] The solvent for preparing the drug solution is not particularly limited, and examples thereof include one or more of water, hydrocarbons such as naphthene, kerosene, and paraffin; alcohols such as glycerin, propylene glycol, dipropylene glycol, hexylene glycol, methanol, isopropanol, 1-octanol, and 1-dodecanol; ketones such as acetone and acetophenone; ethers such as dihexyl ether, diethylene glycol diethyl ether, dipropylene glycol monomethyl ether, dipropylene glycol monobutyl ether, and dipropylene glycol dimethyl ether; esters such as dioctyl adipate, diethyl malonate, and diethyl phthalate; xylene; and silicone oil.

[0041] The amount of drug held in the drug volatilizer 20 may be appropriately determined so as to exert the desired effect (volatility and effective period) taking into consideration the type of drug, etc. Also, the drug volatilizer 20 may be configured as a replaceable cartridge. When the drug volatilizer 10 is used for a long period of time and all or almost all of the drug volatilizes, causing the drug's effect to disappear or decrease, the drug volatilizer 20 can be replaced with a new one to exert the excellent effect again.

[0042] Next, referring to Figures 4(a) and 4(b), the state of volatilization of the medicine when air flows from various directions into the medicine volatilization device 10 will be described. Note that, for convenience, the detailed internal structure of the medicine volatilization body 20 and the like is omitted in the cross-sectional views shown in Figures 4(a) and 4(b).

[0043] As shown in Fig. 4(a), when air flow A flows into the drug volatilization device 10 from the side (the side facing the peripheral portion 31a), part of the air flow A flows out toward the front side (the side where the central portion 31b protrudes) of the drug volatilization device 10 while changing direction along the front surface of the container 30 (the flat region R1 and the curved region R2 described above) as shown by air flow A1. As a result, the air flow comes into contact with the drug volatilization body 20 through the opening 31c provided in the front housing 31 of the container 30, and the drug is appropriately volatilized on the front side of the drug volatilization device 10.

[0044] Furthermore, as shown by air flow A2, another part of the air flow A penetrates the opening 31c of the front housing 31, the drug volatilizer 20, and the opening 32c of the rear housing 32 in the thickness direction, and flows out toward the rear side of the drug volatilization device 10. As a result, the drug is appropriately volatilized toward the rear side of the drug volatilization device 10.

[0045] Furthermore, as shown by air flow A3, a part of the air flow A2 flowing out to the back side of the drug volatilizer 20 passes through the opening 32c of the back side housing 32, the drug volatilizer 20, and the opening 31c of the front side housing 31 again in the thickness direction, and flows out toward the outside in the width direction of the drug volatilization device 10 (the right side in the figure). This allows the drug to be properly volatilized to the outside in the width direction of the drug volatilization device 10.

[0046] 4(b), when air flow B flows into the drug volatilization device 10 from the front side (the side facing the central portion 31b), part of the air flow B, as shown by air flows B1 and B2, flows out toward the outside in the width direction of the drug volatilization device 10 (the side where the peripheral portion 31a protrudes) while changing direction along the front surface of the container 30 (the flat region R1 and the curved region R2 described above). As a result, the air flow comes into contact with the drug volatilization body 20 through the opening 31c provided in the front housing 31 of the container 30, and the drug is appropriately volatilized toward the outside in the width direction of the drug volatilization device 10.

[0047] Furthermore, as shown by air flow B3, another part of the air flow B penetrates the opening 31c of the front housing 31, the drug volatilizer 20, and the opening 32c of the rear housing 32 in the thickness direction, and flows out toward the rear side of the drug volatilization device 10. This allows the drug to be properly volatilized on the rear side of the drug volatilization device 10. Note that even when air flow flows into the drug volatilizer 20 from the rear side, the drug is volatilized along a path substantially similar to that shown in FIG. 4(b).

[0048] As explained with reference to Figures 4(a) and 4(b), by using the drug volatilization device 10, even if the air flow A flows into the drug volatilization device 10 from the side, or even if the air flow B flows into the drug volatilization device 10 from the front side, the drug is appropriately volatilized around the drug volatilization device 10. In other words, the variation in the amount of drug volatilization and the range of volatilization caused by the direction of the air flow flowing into the drug volatilization device 10 is suppressed.

[0049] (Evaluation test of drug volatilization device) Next, tests conducted to evaluate the pest control effect of the chemical volatilization device 10 and the results thereof will be described.

[0050] As an example, a chemical volatilization device 10 was constructed using a container 30 and a chemical volatilization body 20 having the shape described below. A chemical mixture of 250 mg of liquid paraffin as a solvent and 500 mg of transfluthrin as a pest control component was dripped onto the chemical volatilization body 20 to impregnate it. This impregnation amount was converted to 3.6 mg / cm per unit area of ​​the chemical volatilization body 20. 2 It is.

[0051] The container 30 according to the embodiment has a rectangular shape as shown in Fig. 1, Fig. 2, Fig. 3(a) and Fig. 3(b). Specifically, the container 30 has a height of 17 cm in the vertical direction in Fig. 1, a width of 11 cm in the width direction in Fig. 1, and a thickness D of 1 cm as shown in Fig. 3(a). The protrusion amount X (=A / Z) of the container 30 as defined in Fig. 3(a) is 0.27, and the protrusion angle θ of the container 30 as defined in Fig. 3(b) is 29 degrees. The aperture ratio of the opening 31c of the front housing 31 is 30%, and the aperture ratio of the opening 32c of the rear housing 32 is 25%.

[0052] The drug volatilizer 20 according to the embodiment has an overall rectangular shape as shown in Fig. 2. Specifically, the drug volatilizer 20 has a thin plate shape with a height of 14 cm in the vertical direction of Fig. 2, a width of 10 cm in the width direction of Fig. 2, and a thickness of 0.9 mm in the thickness direction of Fig. 2. The drug volatilizer 20 is made of polyester and has a net-like structure.

[0053] As a comparative example, a chemical volatilization device 90 was constructed using a container and a chemical volatilization body having the shape described below. The chemical volatilization body was impregnated with a chemical mixture of 250 mg of liquid paraffin as a solvent and 500 mg of transfluthrin as a pest control component, using the same method as in the above-mentioned example. The amount of impregnation was converted to 3.6 mg / cm per unit area of ​​the chemical volatilization body. 2 It is.

[0054] The container according to the comparative example has a flat shape without a protruding shape like the container 30 according to the embodiment. Specifically, the container according to the comparative example has a thin rectangular parallelepiped shape with a height of 17 cm, a width of 11 cm, and a thickness of 1 cm. This container also has a front housing and a rear housing like the container 30 according to the embodiment, and the aperture ratio of the opening of the front housing is 30%, and the aperture ratio of the opening of the rear housing is 25%.

[0055] The drug volatilizer according to the comparative example has a flat shape corresponding to the container according to the comparative example described above. Specifically, the drug volatilizer according to the comparative example has a thin plate shape with a height of 14 cm, a width of 10 cm, and a thickness of 0.9 mm. This drug volatilizer is made of polyester.

[0056] As shown in FIG. 5, the drug volatilization device 10 according to the embodiment was placed at a height of 100 cm from the floor in the center of a test room (8 tatami mats: length 3.6 m × width 3.6 m × height 2.4 m), and cages containing adult Aedes albopictus mosquitoes (about 20 heads) as test insects were placed at a height of 75 cm from the floor at five locations (first to fifth locations shown by numbers 1 to 5 in the figure) along the wall of the test room. The first location where the cages are placed is on the side of the drug volatilization device 10 (i.e., the side opposite to the side where the air flow flows in). The second location is between the side and front side of the drug volatilization device 10. The third location is on the front side of the drug volatilization device 10. The fourth location is on the back side of the drug volatilization device 10. The fifth location is between the back side and side of the drug volatilization device 10. The drug volatilization device 10 and each cage are placed at an interval of about 1.5 m.

[0057] Then, an air flow with a wind speed of 0.2 m / s was introduced from the side of the drug volatilization device 10, and the time (KT50) until 50% of the test insects were knocked down was measured for each cage. Furthermore, the same test was also conducted for the drug volatilization device 90 of the comparative example. The test results are shown in Table 1 below.

[0058] [Table 1]

[0059] As can be seen from the comparison between the examples and the comparative examples shown in Table 1, there is no substantial difference in the KT50 values ​​between the examples and the comparative examples for the cage position (first position) on the extension line of the air flow and the drug volatilization device 10, but the drug volatilization device 10 according to the examples has a stable knockdown effect even at cage positions (second to fifth positions) that are not on the extension line of the air flow and the drug volatilization device 10 compared to the drug volatilization device 90 according to the comparative example, and it has become clear that the variation in the pest control effect in each cage is small. In other words, even if an air flow flows in from the side of the drug volatilization device 10, the drug is diffused to all points around the drug volatilization device 10, and the pest control effect can be properly exerted.

[0060] These results reveal that the drug volatilization device 10 is able to reduce variation in the amount and range of volatilization of drug caused by the direction of the air flow flowing into the drug volatilization device 10, compared to the comparative drug volatilization device 90.

[0061] <Other aspects> The present invention is not limited to the above-described embodiments, and various modifications can be adopted within the scope of the present invention. For example, the present invention is not limited to the above-described embodiments, and appropriate modifications, improvements, etc. are possible. In addition, the material, shape, size, number, arrangement location, etc. of each component in the above-described embodiments are arbitrary as long as the present invention can be achieved, and are not limited.

[0062] For example, in the above embodiment, the container 30 of the drug volatilizer 20 has the shape shown in Figures 1, 2, 3(a) and 3(b). However, the shape of the container 30 is not limited to the shapes shown in Figures 1, 2, 3(a) and 3(b) as long as the central part 31b away from the peripheral part 31a of the container 30 has a protruding shape in the thickness direction more than the peripheral part 31a in the cross section along the thickness direction of the container 30. For example, the container 30 may have a protruding shape in which the central part 31b protrudes more than the peripheral part 31a as shown in Figure 6(a) and the central part 31b and the peripheral part 31a have a circular arc-shaped protruding shape, or the central part 31b protrudes more than the peripheral part 31a as shown in Figure 6(b) and the central part 31b and the peripheral part 31a have a flat plate-shaped protruding shape. In addition, in the cross-sectional views shown in Figures 6(a) and 6(b), for the sake of convenience, detailed internal structures of the drug volatilizer 20 and the like are omitted. The same applies to the cross-sectional views shown in Figures 7(a) and 7(b) described below.

[0063] Furthermore, for example, the container 30 may have a protruding shape in which a plurality of (two in this example) portions 31d apart from the peripheral portion 31a protrude in the thickness direction from the peripheral portion 31a, and the portions between these portions 31d and the peripheral portion 31a are arc-shaped, and the portions between these portions 31d and the central portion 31b are arc-shaped, as shown in Fig. 7(a). The container 30 may also have a protruding shape in which a plurality of (two in this example) portions 31d protrude in the thickness direction from the peripheral portion 31a, and the portions between these portions 31d and the peripheral portion 31a are flat, and the portions between these portions 31d and the central portion 31b are flat, as shown in Fig. 7(b).

[0064] Here, the features of the above-mentioned embodiments of the chemical volatilization device 10 according to the present invention will be briefly described in the following [1] to [4]. [1] A drug volatilization device (10) including a drug volatilization body (20) holding a drug that is volatile at room temperature, and a container (30) that contains the drug volatilization body (20) and has openings (31c, 32c) that expose the drug volatilization body (20) to the outside, The container (30) is a plate-like structure configured such that, in a predetermined cross section along the thickness direction of the container (30), a portion (31b, 32b, 31d) away from a peripheral portion (31a, 32a) of the container (30) has a protruding shape that protrudes in the thickness direction beyond the peripheral portion (31a, 32a), The drug volatilizer (20) is The protruding shape is curved to fit the protruding shape. Drug volatilization device. [2] In the drug volatilization device (10) described in [1] above, The container (30) is The protruding shape is formed on both the surface on one side and the surface on the other side in the thickness direction. Drug volatilization device. [3] In the drug volatilization device (10) described in the above [1] or [2], The container (30) is The protruding shape in the cross section is configured to be symmetrical about the center of the container (30). Drug volatilization device. [4] In the drug volatilization device (10) described in any one of the above [1] to [3], The drug is At least one selected from the group consisting of profluthrin, empenthrin, transfluthrin and metofluthrin; Drug volatilization device.

[0065] This application is based on a Japanese patent application (Patent Application No. 2019-024600) filed on February 14, 2019, the contents of which are incorporated herein by reference. [Industrial Applicability]

[0066] The drug volatilization device of the present invention can suppress variation in the amount of drug volatilization caused by the direction of air flowing around the drug volatilization device (wind direction). The present invention having this effect can be used, for example, to control pests such as mosquitoes. [Explanation of symbols]

[0067] 10 Drug volatilization device 20 Drug volatilizer 30 containers 31 Front side case 32 Rear side case 31a, 32a Peripheral part 31b,32b central part 31c,32c opening 33 Hanging section

Claims

1. A drug volatilization device comprising a drug volatilization body that holds a drug that is volatile at room temperature, and a container that contains the drug volatilization body inside and has an opening that exposes the drug volatilization body to the outside, The container comprises: The container has a plate-like structure configured such that, in a predetermined cross section along the thickness direction of the container, a portion away from a peripheral portion of the container has a protruding shape that protrudes in the thickness direction beyond the peripheral portion, The drug volatilizer is The protruding portion has a curved shape, The container comprises: The protruding shape in the cross section is configured to be a line-symmetric shape with respect to a central portion of the container. Drug volatilization device.

2. The drug volatilization device according to claim 1, The container comprises: The protruding shape is formed on both the surface on one side and the surface on the other side in the thickness direction. Drug volatilization device.

3. The drug volatilization device according to claim 1 or 2, The drug is At least one selected from the group consisting of profluthrin, empenthrin, transfluthrin and metofluthrin; Drug volatilization device.

Citation Information

Patent Citations

  • Discriminating device

    JP1977052659A

  • Cassette deck

    JP1986082316A

  • Insecticide container for clothing

    JP2005333943A

  • Tubular insecticide transpirator

    JP2008214213A

  • Hanging-type insect repellent container

    JP2009022164A